SOURCE-LINKED STUDY SUMMARY
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- Phase 3 randomized trial comparing two tirzepatide doses with placebo for weight management.
- Who / model studied
- 938 adults with overweight or obesity and type 2 diabetes, treated for 72 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Average weight fell 12·8% and 14·7% with the studied doses versus 3·2% with placebo. At least 5% weight loss occurred in 79 to 83% versus 32%, meeting both primary outcomes. Digestive adverse events were most frequent. Serious adverse events affected 7% overall; two deaths occurred in the lower-dose group and were judged unrelated to treatment by investigators.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(23)01200-x